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Abstract: Persistent hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, 
cirrhosis, and hepatocellular carcinoma and the major indication for liver transplantation in adults. 
Current standard of care treatment (SOC) with pegylated-interferon-α 2 and ribavirin (RBV) 
has a limited efficacy and is associated with significant side effects frequently associated with 
poor compliance or treatment discontinuation, requiring specialized and frequent monitoring. 
To overcome the limited efficacy of SOC, more than 50 direct-acting antiviral agents (DAA) 
designed to target viral-encoded proteins essential in the HCV life cycle are currently under 
development. The rapid selection of resistant mutants associated with the quasispecies nature of 
HCV with high mutation and replication rates is one of the main challenges for the new HCV 
therapies. Predictive host and viral factors together with combination of DAAs with or without 
IFN and/or RBV need to be accurately evaluated to design the most effective individualized 
treatment strategy within the shortest time interval and with minimum side effects.
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Introduction
An estimated 200 million people are infected with the hepatitis C virus (HCV) world-
wide, a prevalence fivefold higher than that of human immunodeficiency virus (HIV).1,2 
Chronic HCV infection (CHC) is one of the leading causes of chronic hepatitis, cir-
rhosis, and hepatocellular carcinoma (HCC). HCV-associated end-stage liver disease 
and/or HCC account for more than 50% of adult liver transplantation cases in Western 
countries,3 and HCV-associated disease burden is expected to exponentially increase 
in the next decades. Epidemiological studies draw a future gradual decline in the 
infected population; however, the number of patients with HCV-associated cirrhosis 
and its complications is expected to increase exponentially during the next decades.4 
A mathematical model has been used to project, over the next 30 years, the HCV-
related complications and costs in a cohort of 419,895 infected patients,   representing 
the HCV-infected population in Spain. The model predicts a gradual decline in the 
infected population, but the proportion of patients with cirrhosis will increase by up 
to 14% and morbidity associated with HCV infection by up to 10% by the year 2030. 
The same model predicted that treating from 10% to 50% of the HCV population using 
standard therapy will result in a reduction of 6% and 26% in morbidity and 4% and 
20% in mortality in the next decades.5
In contrast to HBV and HIV , HCV does not integrate into the host genome and 
treatment is aimed at viral eradication rather than suppression of viral replication.6 
Indeed, sustained viral response (SVR), defined as undetectable serum HCV RNA Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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6 months after treatment completion, has been shown 
to halt progression to cirrhosis7 in the vast majority of 
patients. Furthermore, viral eradication among patients 
treated when cirrhosis has already established signifi-
cantly reduces the risk of hepatic decompensation and 
HCC,8 increasing survival and reducing the need for liver   
transplantation.
The current standard of care (SOC) treatment for CHC is 
the combination of pegylated-interferon-α 2b (peg-IFN-α 2b, 
PegIntron®; Merck (MSD), Whitehouse Station, NJ) or 2a 
(peg-IFN-α 2a, Pegasys®; Roche, Berlin, Germany) with 
weight-adjusted ribavirin (RBV). The rates of SVR achieved 
with peg-IFN-α and RBV are genotype dependent, with 
∼80% of genotypes 2- and 3-infected patients achieving SVR 
after 6 months of treatment and ∼50% of genotypes 1- and 
4-infected patients treated for 48 weeks.9 Unfortunately, 
HCV genotype 1, the most prevalent worldwide,10–13 is also 
the less responsive to current treatment, with no significant 
differences in SVR rates between the two available peg-IFN 
+ RBV formulations.12 In addition to its limited efficacy, 
SOC treatment is associated with significant side effects,14 
frequently requiring dose reduction or treatment discontinu-
ation (10%–15% of patients), with a significant decrease 
in SVR rates, or even precluding their use in patients with 
certain comorbidities (ie, major psychiatric conditions, renal 
insufficiency, and/or cardiac disease).4 Therefore, the lim-
ited efficacy of peg-IFN + RBV therapy, especially against 
HCV genotype 1, together with side effects and treatment 
contraindications in many patients and a lack of an alterna-
tive to present therapy have led to the use of many adjunctive 
pharmacotherapeutic agents.
This review will highlight the most promising new drug 
treatments under advanced clinical trials, the need to evalu-
ate predictive host and viral factors, and new combination of 
agents with or without IFN and/or RBV to improve antiviral 
efficacy.
Emerging treatments
Emerging treatments have been focused on improving the 
existing armamentarium in the form of modified or alterna-
tive IFN and RBV preparations, identifying new inhibitors 
of HCV , defining new regimens of antiviral combinations, 
and looking for predicting factors of SVR.
New IFN and RBv preparations
The basic requirements for newly developed agents are to 
increase efficacy, to reduce duration of treatment, to reduce 
toxicity and facilitate accomplishment of treatment, and 
to allow treatment of patients with IFN contraindications   
(Table 1).
IFN-λs
IFN-λs are type III interferons (IFNs) that have been shown to 
upregulate major histocompatibility complex (MHC) class I 
antigen expression and induce antiviral protection, antiprolif-
erative, antitumor, and immune responses, as well as activation 
of IFN-stimulated genes.15,16 The correlation between SVR 
rates and a single nucleotide polymorphism (SNP) situated in 
the IL28B genomic region (see below) in genotype 1 HCV-
infected patients treated with SOC highlighted the IFN-λ 
signaling axis as a potential target for novel antiviral drug 
development. Initial studies showed that IFN-λ1 (IL29) and 
IFN-λ2 (IL28A) blocked HCV replication in human hepa-
tocytic cell lines.17–19 In a Phase Ib trial of responders/relaps-
ers chronic HCV patients, the drug showed a robust activity 
against HCV and a low toxicity, which may be explained by a 
much more restricted tissue distribution of the IFN-λ receptor 
compared to that of the IFN-α receptor. Phase IIb studies with 
different IFN-λ doses in combination with RBV (daily) have 
started including patients chronically infected with genotypes   
1 to 4.
Interestingly, there is in vitro evidence that anti-HCV 
activity of IFN-λs and IFN-α is enhanced by a low dose of 
the other, which suggests that both IFNs may interact playing 
a complementary role in the suppression of HCV .17,20
Albumin-IFN-α
Recombinant human slow-release type 1 albumin-IFN-α is 
a novel 85.7-kD recombinant protein consisting of IFN-α-2b 
genetically fused to human serum albumin (Albuferon; 
Human Genome Sciences Inc., Rockville, MD, USA/Novartis 
AG, Basel, Switzerland) named Zalbin in the United States 
and Joulferon in Europe. The advantage of Albuferon is a 
longer mean life that allows regimens of dosage every 2–4 
weeks. Phase III studies reported similar results in SVR 
Table 1 Novel interferon (IFN) and ribavirin (RBv) preparations
Class Agent Phase of 
development
Type III IFN IFN-λ1 (IL-29) Phase IIb
IFN
Slow-release 
type I IFN
Albuferon Zalbin (USA)
Under 
review
Joulferon (eU) Halted
Locteron (BLX-883) Phase II
Oral IFN-α Belerofon Phase II1
RBv RBv prodrug TBv Phase III
Note: 1Phase II 2007.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
135
New strategies for the treatment of HCv
rates21 than standard peg-IFN-α 2 in SOC treatment. However, 
observation of respiratory adverse events has prompted the US 
Food and Drug Administration (FDA) to raise some questions 
about the benefit–risk assessment. Recently (in June 2010), the 
manufacturer formally withdrew Albuferon® from European 
license procedure, and also in the United States following the 
61st Meeting of AASLD in Boston.79
Other IFN preparations
Locteron® (Biolex, Pittsboro, NC/OctoPlus, Leiden, The 
Netherlands) is a microsphere-based controlled-release of 
unpegylated IFN-α 2b recombinant formulation that allows 
regimens of dosage every 2 weeks. Clinical trials combining 
Locteron® + RBV have reported similar results than peg-IFN + 
RBV over 12 weeks of treatment and with less fewer flu-like 
side effects.22 Some other promising preparations such as 
Belerofon® (Nautilus Biotech, Evry, France), a slow-release 
IFN preparation that can be orally administrated, omega 
IFN (Intarcia Therapeutics, Hayward, CA),23 a type1 IFN 
that has been tested for anti-HCV effect using an implant-
able infusion pump (Duros device) for the continuous 
delivery and consistent dose of drug for 3–12 months,24 or 
Consensus IFN (CIFN),25 an artificially engineered IFN, 
despite having promising reports, have not reached a final 
approval or been extensively commercialized for different   
reasons.
RBv
RBV is still an essential drug in all present anti-HCV regi-
mens. RBV has antiviral efficacy, measured by clearance of 
HCV RNA, when used in combination with IFN.
The impact of RBV on HCV infection remains poorly 
understood. It has been suggested that RBV acts clini-
cally by promoting nonviable HCV RNA mutation rates 
and is capable of driving replicating virus into error 
catastrophe.26–29 The combination therapy of RBV with IFN 
was superior than RBV monotherapy in inducing nucleic 
acid substitutions.29 The principal specific side effect caused 
by RBV is anemia, and it is frequently detected during 
combination peg-IFN + RBV treatment. Anemia is one 
of the reasons for discontinuation of treatment and makes 
many patients with contraindications, such as patients with 
renal insufficiency and/or cardiac diseases, ineligible.4 To 
improve efficacy, tolerability, and reduce RBV-associated 
anemia,30 liver-targeting RBV prodrugs are under devel-
opment. Among them, taribavirin (TBV) (Viramidine®; 
Valeant Pharmaceuticals, Aliso Viejo, CA) is a prodrug that 
is metabolized by the liver to the active metabolite, thereby 
limiting the red blood cell effect and reducing anemia 
caused by standard RBV. A comparative clinical Phase IIb 
study of RBV versus TBV both combined with peg-IFN-α 
2b revealed that when doses were adjusted to body weight, 
the combination peg-IFN-α 2b + TBV achieved comparable 
virological response rates than standard peg-IFN-α 2b + 
RBV treatment, but with the advantage that TBV caused 
less anemia (7%–15% of peg-IFN + TBV-treated patients 
compared with 24% treated with peg-IFN + RBV).31 Sec-
ondary effects such as diarrhea were more common with 
TBV but were generally mild and not dose limiting. Clinical 
Phase III trials are in process.
New inhibitors of HCv
Manipulation of immune response either 
innate or adaptive
Preliminary data exist for direct immune stimulants, both 
innate and adaptive, as well as therapeutic vaccines. Spe-
cifically enhancing adaptive immunity against HCV-specific 
epitopes with concomitant alteration of the cytokine milieu 
represents multiple opportunities for drug design, but 
manipulation of immune response which represents a tightly 
regulated system represents a delicate balance and can result 
in severe secondary effects (reviewed by Schinazi and cowork-
ers32). A more specific therapeutical approach needs deeper 
knowledge of HCV biology since several HCV proteins 
(core, envelope, NS3, and NS5A) may interfere/inhibit IFN-
α-induced activation of the JAK–STAT pathway, which is a 
critical transducer of IFN-α-mediated signaling and serves 
as a global director of the IFN-α-driven innate immune   
response.33–35
Many classes of immunomodulators are under various 
stages of clinical investigation, including polyclonal antibod-
ies, interleukin therapy, broad-spectrum anti-inflammatory 
agents, and nonspecific immune enhancers such as toll-like 
receptor targets, thymosin α1, 3-hydroxy-3-methylglutaryl-
CoA reductase inhibitors, the monoclonal antiphosphatidyl-
serine bavituximab (Peregrine Pharmaceuticals, Inc., Tustin, 
CA), the dipeptide l-Glu-l-Trp oglufanide (Implicit BioSci-
ence, Toowong, Australia), SCV-07 (SciClone Pharmaceuti-
cals, Inc., Causeway Bay, Hong Kong), and the antiprotozoal 
nitazoxanide.32,36,37
Several therapeutic vaccines are under development. 
GI-5005 (GlobeImmune, Inc., Louisville, CO) has recently 
finished Phase IIb trial and results show that in triple therapy, 
peg-IFN + RBV + GI-5005 increased the SVR in genotype 
1 IFN-naive patients (58%) compared to patients receiving 
peg-IFN + RBV alone (48%).Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Inhibition of host-encoded targets  
essential for viral replication
A number of host-encoded targets essential for HCV 
  replication have been identified, of which enzymatically 
active cyclophilin A is the most advanced. It is required for 
HCV replication and processing kinetics.38 One promising 
drug showing potent anti-HCV function is cyclosporine A 
(CsA) because of its high affinity to cyclophilins (CyPs), but 
it is a powerful immunosuppressive drug39 due to its ability 
to block the phosphatase calcineurin. Because of the nonim-
munosuppressive properties combined with profound antiviral 
activity, CsA derivatives such as Debio-025 (alisporivir; 
Debiopharm SA, Research Triangle Park, NC),40,41 NIM811 
(Novartis, Basel, Switzerland),42 and SCY-635 (Scynexis, 
Durham, NC) are more likely to be used as anti-HCV agents. 
Unlike CsA, these molecules bind to CyPs but do not dis-
play calcineurin inhibition and have demonstrated clinical 
antiviral activity against HCV .43 Clinical Phase IIb trials are   
ongoing.
Recent in vitro assays reveal that the combination of 
Debio-025 with either RBV or another inhibitor (see below) 
in the absence of IFN resulted in additive antiviral activity 
in short-term antiviral assays, delaying or preventing the 
development of resistance to HCV protease inhibitors as well 
as to nucleoside and nonnucleoside polymerase inhibitors. 
This result will improve efficacy in the treatment of patients 
with severe contraindication to IFN treatment.
Debio-025 is an attractive drug candidate for the treat-
ment of HCV infections in combination either with standard 
IFN-based treatment and/or treatments that directly target the 
HCV polymerase and/or protease.44
Use of microRNAs to regulate HCv expression 
(microRNA-122)
MicroRNAs (miRNAs) are key regulators of gene expres-
sion at a post-transcriptional level. The liver-expressed 
  microRNA-122 (miR-122) seems essential for HCV RNA 
accumulation in cultured liver cells since it stimulates its 
replication by binding to the 5′ noncoding RNA region 
(5®NCR), which is highly conserved in all six HCV geno-
types. Treatment of chronically infected chimpanzees with 
a locked nucleic acid-modified oligonucleotide (SPC3649; 
Santaris Pharma, Hoersholm, Denmark) complementary to 
miR-122 leads to long-lasting suppression of HCV viremia, 
with no evidence of viral resistance or side effects in the 
treated animals. Conservation of both miR-122 seed sites in 
all HCV genotypes and subtypes suggests that such therapy 
will be genotype independent.45 However, miR-122 has been 
regarded as the negative regulator of gene expression in, for 
example, cell differentiation, proliferation, migration, and 
invasion. Recent studies have revealed that miR-122 plays 
an important role in the regulation of intrahepatic metastasis 
of HCC46 and that it is downregulated in both primary and 
metastatic HCC.47,48
Therefore, miR-122-based therapeutics might be a 
double-edged sword for the treatment of HCC in HCV-
infected patients and inadvisable for the basic treatment of 
HCV-infected patients.
Hepatitis C
virus life cycle
Drug discovery
HCV attachment and entry
(+) (+/−)
HCV viral
replication
HCV-RNA translation
HCV-RNA post-translation
processing
Viral assembly
and release
Figure 1 Hepatitis C virus life cycle and putative targets to design specific drugs.
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Inhibitors of HCV life cycle steps
All proteins encoded in the small HCV genome are essential 
for viral propagation and very attractive for therapy since 
inhibition of these viral proteins does not mainly affect 
cellular functions. Putative targets to design specific drugs 
include inhibitors of all steps in the HCV life cycle: viral 
entry, HCV RNA translation and post-translational pro-
cessing, HCV replication, and viral assembly and release 
(Figure 1 and Table 2).
Inhibitors of viral attachment and entry
Several receptors have been associated with HCV-specific 
attachment and entry to the hepatocyte. It has been proposed 
that the first step includes the cell surface contact through 
the heterodimeric E1 and E2 proteins. Both glycoproteins 
are expressed on the virus envelope that is associated with 
low- and very-low-density lipoprotein (vLDL).49 Initial host 
cell contact is mediated by interaction with the low-density 
lipoprotein receptor (rLDL) and/or glycosaminoglycans. 
E2 also binds to dendritic cell-specific intercellular adhe-
sion molecule-3-grabbing nonintegrin and liver/lymph 
node-specific intercellular adhesion molecule-3-grabbing 
integrin; the asialoglycoprotein receptor may also interact 
with HCV structural proteins.50–56 The virus subsequently 
binds to high-affinity receptors, including scavenger receptor 
class B type I and the tetraspanin protein CD81, through the 
ecto-domain of E2. It then binds to claudin 1 and occludin, 
both of which are expressed at tight junctions of polarized 
hepatocytes.57,58 Internalization of the virus proceeds through 
clathrin-dependent endocytosis, and viral membrane fusion 
takes place in the acidified endosome, a pH-dependent 
mechanism.59 This releases the viral core into the host cytosol, 
where uncoating and disassembly of the virus capsid releases 
the RNA genome. To date, numerous entry inhibitors are in 
various stages of preclinical development and are reviewed 
by Schinazi and coworkers.32 Among them d,l-a-peptides 
have shown activity in genotypes 1a, 1b, and 2a in vitro,60 
and CD81mAb in liver-uPA-SCID mice model, but admin-
istration of anti-CD81 antibodies after viral challenge had 
no effect.61 Inhibition of viral entry into HCV-permissive 
cells could provide an efficacious mechanism for reduction 
or elimination of viral infection, but blocking cellular recep-
tors with important biochemical functions for the hepatocyte 
without differentiating between infected and noninfected 
hepatocytes may cause important negative effects on the 
normal functionality of the liver.
Inhibitors of viral assembly
Core (191aa) acts as the viral nucleocapsid and RNA packag-
ing. It has good sequence conservation across isolates, and 
the protein is poorly structured prior to assembly. However, 
core–core interaction avidity can reduce potency of any 
inhibitors in vivo. HCV assembly starts with recruitment of 
the core protein and NS5A to the surface of lipid droplets, 
followed by delivery of HCV RNA from the HCV replication 
complex to the nascent viral particle.62,63 However, nonspe-
cific inhibitors targeting this region have not yet proved the 
proof of principle in clinical trials.
Alteration of proper envelope protein folding of many 
viruses has been obtained using α-1 glucosidase I inhibitors.64 
Phase IIa clinical investigation using one of these inhibitors 
named celgosivir (Megenix Inc., Vancouver, Canada) has 
demonstrated potency against both HCV and HBV ,64 but 
studies have been cancelled.
Table 2 Some of the most promising direct-acting antiviral agents
Viral life  
cycle step
Target Agent Phase of 
development
Post-translational 
processing
NS3/4A  
protease
Telaprevir  
(vX-950)
Phase III1
Boceprevir 
(SCH503034)
Phase III1
GS-9256 Phase II
BI 201335 Phase II
RG7227  
(Danoprevir)
Phase II
vaniprevir  
(MK-7009)
Phase II
Narlaprevir 
(SCH900518)
Phase II
TMC435 Phase IIa
BMS-650032 Phase II
BMS-791325 Phase II
Danoprevir Phase II
ABT-450 Phase II
NS3 helicase BTN10/BTN11 Preclinical
Replication NS5A AZD-7295 Phase II
BMS-790052 Phase II
A-832 Phase II
NS5B (NI) RG-7128 Phase II
PSI-7977 Phase II
Tegobuvir Phase II
IDX184 Phase II
NS5B (NNI) GS-9190 Phase II
ABT-333 Phase II
ANA598 Phase II
BI-207127 Phase II
ABT-072 Phase II
Filibuvir  
(PF-00868554)
Phase II
vCH-916 Phase II
vX-222 Phase II
vX-759 Phase II
Note: 1Putative final approval in 2011.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Inhibitors of RNA translation,  
post-translation, and replication
Internal ribosome entry site, p7, and NS2 inhibitors
The internal ribosome entry site (IRES), the initiation of 
cap-independent translation of HCV , serves as a direct regu-
lator for assembly of initiation of translation complexes on 
viral mRNA. It is highly conserved and structured. As this 
mechanism is distinct from those observed in prototypical 
  eukaryotic translation machineries, the inhibition of viral 
IRES could provide a virus-specific target for antiviral 
compounds. Specific inhibitors of IRES HCV translation, 
either RNA molecules (chimeric HH363 that target essen-
tial domain IV stem-loop position 363) that interfere with 
formation of a translationally active complex or DNAzymes 
(specific molecules with cleavage activity) or small molecules 
that bind p7 (63aa, ion channel or porin with low sequence 
conservation) and NS2 (217aa, cysteine autoprotease), have 
reported activity in cell culture,65 but none has yet reached 
development. Antisense RNAs specific for the IRES have 
not yet led to a proof of principle in clinical studies.32
NS3-NS4A-NS4B-NS5A-NS5B inhibitors
More than 50 new drugs specific against HCV named 
direct-acting antiviral agents (DAAs) (also known as specifi-
cally targeted antiviral therapy for hepatitis C or STAT-C) are 
under advanced clinical trials to be used either as an adjunct 
to current SOC therapy in triple, quadruple, or multiple 
combination or in place of it in patients with SOC severe con-
traindications. In the next 2 years, it will likely become stan-
dard for treatment either in naive or in pretreated patients.66 
Among them, DAAs targeting NS3, NS5A, and NS5B have 
demonstrated proof of principle for viable targets.
NS3
NS3 is essential for viral replication. It is a multifunc-
tional protein that harbors a serine protease located in the 
N-  terminal one-third (189aa) involved in cis-cleavage of 
NS3–NS4A site, and the NS3 forming an heterodimer 
with NS4A is responsible for the downstream cleavage of 
the NS4A/4B, NS4B/5A, and NS5A/B junctions in the non-
structural region. The C-terminal two-thirds of NS3 have an 
NTPase/RNA helicase domain (442aa).
NS3 protease
NS3 serine protease activity is essential for cleavage of the 
large HCV polyprotein into active peptides that in turn are 
critical in forming the replicative complex from which viral 
RNA synthesis occurs.67–70 The NS3/NS4A serine protease 
also blocks activity of IFN regulatory factor 3 (IRF3), the 
critical transcription factor required for virus-induced IFN 
production.71 Therefore, the NS3 represents a dual therapeutic 
target, the inhibition of which may both block viral replication 
and restore hepatocyte IRF3 control of HCV infection.72
The serine protease inhibitors telaprevir (VX-950;   Vertex, 
San Diego, CA) and boceprevir (SCH503034; Schering-
Plough, Whitehouse Station, NJ) are the most advanced 
DAAs in clinical studies.
Phase II clinical trials using triple therapy with 
peg-IFN-α + RBV + telaprevir (TPR) (termed PROVE 1 
for the US study73 and PROVE 2 for the European one74) 
or boceprevir (BPR) (SPRINT) have shown an important 
increase in SVR rates and a decrease in breakthrough and 
relapse rates, being highest in patients who did not achieve 
a rapid virological response at week 4 with SOC therapy.75 
The addition of a potent protease inhibitor to the SOC treat-
ment considerably accelerates the first slope of viral decline 
during the first few days of therapy.76–78
The Phase IIb studies (PROVE 1 and PROVE 2) in HCV 
genotype 1 patients showed that double combination TPR 
and peg-IFN-α had low efficacy (SVR rates of 41%–46% 
PROVE 1 and 2, respectively) and higher relapse (22%–23%) 
than triple therapy adding RBV (SVR rates 61%–69% and 
relapse 2%–14%). Therefore, the first conclusion of this trial 
was that RBV is still an essential drug for these anti-HCV 
regimens. Another important conclusion was that adminis-
tration of TPR for 12 weeks followed by 12 weeks of SOC 
yields superior SVR rates with shorter duration of therapy 
compared to SOC treatment.73,74
In the case of BPR, triple combination was compared 
with SOC treatment in the SPRINT-1 study. A key aspect 
of this trial was the assessment of a 4-week SOC lead-in 
phase before the introduction of BPR in triple therapy. The 
rationale for this approach was to establish antiviral activity 
before adding BPR with the hope of minimizing the risk of 
emergent drug resistance, followed by 44 weeks of triple 
therapy with BPR (for a total of 48 weeks of treatment). The 
most important finding from this analysis was that 44 weeks 
of BPR following the 4-week lead-in phase was associated 
with the highest SVR rate of 75% compared to 38% with 
SOC (P , 0.0001). The next highest SVR rate was 67%, 
which was achieved by patients receiving the 48-week triple-
combination regimen that did not include lead-in treatment 
(P , 0.0001 versus SOC). The proportion of patients who 
achieved SVR with 24 weeks of triple therapy following a 
4-week lead-in phase was 56% (P = 0.0005 versus SOC) 
versus 54% with 28 weeks of triple therapy and no lead-in Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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treatment (P = 0.013 versus SOC). BPR seems to be quite 
effective in this context, and the triple-combination regimen 
with the 4-week lead-in phase has been selected for further 
evaluation in Phase III clinical trials.
In both TPR and BPR treatment clinical trials, the 
improved efficacy comes with additional side effects, par-
ticularly rash and increased anemia, and a risk of   selecting 
drug-resistant viral variants that may limit subsequent 
therapeutic options.75,79 As a result, response-guided therapy 
has been adopted in the design of the Phase III trials either 
using TPR or BPR.
The recently reported Phase III study named ADVANCE 
(Vertex) using TPR is an example of a response-guided trial. 
Seventy-five percent of patients infected with HCV1 who 
were not previously treated achieved an SVR after receiving 
12 weeks of TPR in triple therapy followed by a course of 
SOC therapy for at least another 12 weeks. In the ADVANCE 
trial, in the TPR group, if the virus was sufficiently sup-
pressed after 4 weeks, patients received only 24 weeks of total 
treatment (half the standard treatment time). Notably, about 
70% of those who achieved SVR only received 24 weeks of 
therapy. Patients in the control group underwent standard 
therapy for 48 weeks and 44% achieved an SVR.
In the case of BPR, Phase III trials have been focused 
on treating genotype 1 patients who were nonresponders 
or relapsers to prior therapy comparing SOC treatment 
(arm1) with response-guided therapy receiving BPR in 
triple therapy for 32 weeks, and those HCV RNA positive 
at week 8 received an additional 12 weeks of SOC (arm2), 
and BPR of 44 weeks (arm3). There was a significant 
absolute increase in SVR compared with SOC of 37.4% 
in arm2 and 45.2% in arm3.
Phase III results from either TPR or BPR in triple therapy 
fuel hopes for major improvements in treatment outcomes 
increasing the cure rate by more than 30%.75,79,80
To improve the pharmacokinetic profile, dosing inter-
vals, and perhaps some advances in safety and tolerability,80 
second-generation protease inhibitors taken once a day 
(at present TPR and BPR have to be taken orally three 
times a day) are in Phase II trials. Some of these new-wave 
NS3 protease inhibitors include the following: BI-201335 
(Boehringer Ingelheim, Ingelheim am Rhein, Germany), 
BMS-650032 (Bristol-Myers Squibb, New York, NY), 
GS-9256 (Gilead, Foster City, CA), Danoprevir/R7227/
ITMN191 (InterMune, Brisbane, CA/Roche) and NS3/
NS4 A inhibitors ABT-450 (Abbott, Abbott Park, IL/
Novartis), and Vaniprevir/MK7009 (Merck) among many   
others.
A conclusion extracted from the clinical trials using DAAs 
has been that in order to improve efficacy, reduce duration 
of treatment, and facilitate accomplishment of treatment, 
response-guided therapies should be faced by using predic-
tive values. Virologic response rates have been shown to 
depend on various baseline host and viral factors such as age, 
weight, gender, race, liver enzymes, stage of fibrosis, HCV 
genotype, and HCV RNA concentration at baseline10,11,81–85 
and also on treatment factors at the time of HCV RNA 
clearance. Among chronically infected patients, response 
to treatment differs, even among cases with similar HCV 
RNA levels and identical viral genotypes,10,11,86,87   suggesting 
that other factors should be taken into consideration. A 
recent genome-wide association study with 1671 individuals 
infected with HCV genotype 1 showed that genetic variation 
in the IL28B gene, which encodes IFN-λ, is associated with 
spontaneous HCV clearance88 and therapy response to SOC 
treatment.89–91 Particularly, the presence of a C/C genotype 
in the SNP rs12979860 located on chromosome 19q13 was 
strongly associated with an SVR. The corresponding SVR 
rates being ∼80% for the C/C genotype, ∼40% for the T/C 
genotype, and ∼30% for the T/T genotype aimed at identifying 
genetic contributions to anti-HCV response.89,92 It has been 
recently shown that rs12979860 genotype is a significant 
predictor of SOC response in CHC patients independent of 
HCV genotype and other covariates.93 Interestingly, in a ran-
dom multiethnic population of 455 patients, the C-allele fre-
quency was ∼90% in East Asian patients, ∼55% in European 
American patients, and just ∼25% in African–Americans. This 
finding finally sheds some light on the precise mechanisms 
that are behind the significantly lower SVR rates obtained in 
African–Americans compared with Caucasians94,95 and the 
higher SVR rates consistently reported in trials of anti-HCV 
therapy conducted in Asia.96 The association between SNPs 
in the IL28B region and SVR in HCV-1-infected patients has 
been confirmed by different studies.20,88–90,95 A more fine map-
ping revealed seven SNPs associated with NVR: rs8105790, 
rs11881222, rs8103142, rs28416813, rs4803219, rs8099917, 
and rs724866891 that need further analysis.
NS3 helicase
The carboxy terminal, two-thirds of NS3, constitutes the 
helicase domain, which is also essential for the replication 
of viral RNA. The helicase domain might stimulate the activ-
ity of NS5B polymerase, resolve RNA secondary structure 
immediately prior to replication by the polymerase, and/or 
separate newly synthesized double-stranded RNA into posi-
tive and negative strands. Two tropolone derivatives, BTN10 Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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and BTN11,97–100 and trixsalen101 have significant antiviral 
activity in the HCV replicon system.
NS4A
NS4A is part of the NS3 protease structure and acts as a 
  membrane anchoring the replication complex. No   structural 
information is known, except that the central   portion binds 
to NS3. It may be a ‘druggable’ target.
NS4B
NS4B possibly has an important activity in the formation 
of membranous web structure and assembly of replication 
complex and/or NTPase. It is among the key players in 
the HCV replication cycle and hypothesized to bind RNA. 
A nucleotide binding motif was identified within NS4B to 
bind and hydrolyze GTP,102 and it is suggested that it may 
also bind polynucleotide structures. It is a hydrophobic and 
poorly structured protein and may represent a challenge for 
biochemical analysis and antiviral targeting. In fact, ATPases 
and GTPases have previously been targeted successfully. 
Recently, high-throughput screening for inhibitors of the 
RNA binding function has identified an H1 histamine recep-
tor antagonist (clemizole hydrochloride) that substantially 
inhibits HCV replication in cell culture. This approach for 
drug discovery seems useful when dealing with membrane-
bound protein targets.103
NS5A
NS5A is a multifunctional protein with critical viral key 
functions, regulation of HCV RNA replication, virus 
assembly, multiple viral–viral and viral–host protein interac-
tions, modulation of cellular signaling pathways, and IFN 
response.104 It contains a putative IFN sensitivity-determining 
region and may play a role in resistance to IFN-α.105 As a 
multifunctional protein required for in vivo and in vitro rep-
lication with unknown human homologues, NS5A represents 
an attractive target for therapeutic intervention. Proof of 
principle for NS5A as a viable target has been demonstrated 
in early clinical trials in HCV-infected subjects. Two potent 
NS5A DAAs compounds, AZD-7295 (AstraZeneca, Madrid, 
Spain) and BMS-790052 (Bristol-Myers Squibb), have been 
evaluated in Phase II clinical trials. BMS-790052 has shown 
strong activity against several genotypes106 in replicon and 
JFH-1 systems, and it has demonstrated a rapid and robust 
HCV RNA decline (∼3.6 log 10) in clinical trials with no 
signs of adverse effects.107 Promising results from clinical tri-
als provide the basis for designing second-generation NS5A 
polymerase inhibitors.108
NS5B, RNA-dependent RNA polymerase
Although protease inhibitors are expected to reach the market 
first, investigational agents that block other HCV enzymes, 
such as NS5B protein, are of special interest because NS5B 
specifically catalyzes viral RNA synthesis and genome 
replication. Proof of principle for NS5B as viable target has 
been demonstrated in clinical trials. Inhibitors of HCV NS5B 
RNA-dependent RNA polymerase (RdRp) are divided into 
two classes: nucleoside and nonnucleoside inhibitors (NI 
and NNI, respectively). Nucleoside polymerase inhibitors in 
particular appear to have a high genetic barrier to resistance, 
but the nonnucleosides also offer great promise in combina-
tion with other drugs.
NI: In their active triphosphate forms, NI metabolites act as 
nonobligate chain terminators while competing with the natu-
ral substrate nucleotides for the HCV NS5B RdRp, thereby 
reducing the efficiency of further RNA elongation through 
steric resistance. To date, many NI polymerase inhibitors 
are under early stages of clinical investigation,32,80 and the 
most advanced ones, which are in Phase II, include RG-7128 
(Pharmasset, Princeton, NJ/Roche),   PSI-7977 (  Pharmasset/
Roche), Tegobuvir (Gilead), and IDX184 (Idenix Pharma-
ceuticals, Cambridge, MA).
NNI: The primary mechanism of action for NNI is spe-
cific targeting of different and less-conserved allosteric 
sites of the HCV NS5B polymerase. Multiple NS5B HCV 
inhibitors are under clinical investigation, and the ones 
that are in Phase II include GS-9190 (Gilead), ABT-333 
(Abbott Laboratories), ANA598 (Anadys Pharmaceuti-
cals, San Diego, CA), BI-207127 (Boehringer Ingelheim), 
ABT-072 (Abbott Laboratories), Filibuvir/PF-00868554 
(Pfizer, New York, NY), VCH-916, and VX-222 (Vertex   
Pharmaceuticals).32,80
SOC-free treatments
Side effects caused by SOC contraindicated treatment of 
many patients. It is clear that monotherapy with a DAA is not 
possible because resistance mutants appear in a few days of 
treatment. In this scenario, researchers are looking at using 
combinations of DAAs targeting different viral functions 
for which there is no cross-resistance, as has been success-
fully applied at preventing resistance in HIV treatment. The 
basic knowledge for this approach is that to get resistance, 
a combination of two drugs needs to be developed, which 
is obviously much less likely than with just one drug.109 At 
this moment, whether SOC-free regimens are possible and, 
if they are, what will be the best combinations of DAAs, 
needs further study.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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The first IFN/RBV-free regimen trial (INFORM-1) was 
performed by combining the HCV protease inhibitor RG7227 
(also known as ITMN-191) with the polymerase inhibitor 
RG7128 (Roche/Genentech, San Francisco, CA) and results 
showed that over the course of a 14-day study, there was an 
HCV viral load reduction below the limit of   quantification in 
63% of subjects enrolled,110 opening the possibility to treat 
patients with contraindications to IFN and/or RBV treat-
ments. Other combinations that are under study include BMS-
650032 (NS3 inhibitor) with BMS-790052 (NS5A inhibitor) 
by Bristol-Myers Squibb or GS9256 (protease inhibitor) with 
tegobuvir (NI NS5B inhibitor) by Gilead80 (Table 3).
Antiviral drug resistance
Antiviral drug resistance mutations, especially to new DAAs, 
cause an important drawback in the treatment of chronic 
infection. The primary factor involved in viral resistance is 
the quasispecies nature of HCV , a consequence of the high 
viral turnover via the error-prone polymerase. HCV has a 
half-life of only 2–5 h, with the production and clearance of 
1010–1012 virions/day in an infected patient.111,112 The enzyme 
used for the HCV for replication (RdRp codified by the NS5B 
genetic region) has poor fidelity and lacks an exonucleolytic 
proofreading mechanism; replication is, therefore, inherently 
error-prone, with an error-rate in the order of 10−3–10−4 muta-
tions/site and genomic replication cycle (corresponding to a 
natural evolutionary rate of 1.5 × 10−3 base substitutions/site/
year).113,114 As a consequence of high mutation rate and high 
level of replication, the virus circulates as a complex mixture 
of different but closely related genomes known as quasispe-
cies in the infected host.115 Quasispecies represents a highly 
dynamic structure with mutants continuously arising, all 
competing but interacting (they may cooperate) and displaying 
different phenotypes and fitness.116 Single mutations at each 
position in the genome arise at least once every day, and in 
consequence, potentially drug-resistant mutants are constantly 
being generated. Since antiviral-resistant mutants are often 
less replication-competent than the corresponding wild-type 
(wt) viruses, they represent minority mutants in the absence 
of drug therapy. During antiviral treatment, such mutants are 
selected and arise as major components of the viral quasispe-
cies contributing to treatment failure. Besides, compensatory 
mutations selected in the same genome contribute to fitness 
recovery.117,118 On stopping the treatment, if such mutations 
are less competitive than others, they might be negatively 
selected and relegated to a minority population, but remaining 
at a higher proportion than before, generating a memory in 
the quasispecies. It has been recently reported that a resistant 
variant may persist for at least 3 years following a 14-day trial 
with DAA monotherapy.119 If the patient is then retreated with 
the same drug or with a cross-reactive one, the HCV-resistant 
variant rapidly emerges, within days, thus contributing to a 
rapid treatment failure.120 Therefore, the use of any DAAs in 
monotherapy should not be ever considered since resistance 
develops within the first day of treatment with the risk of 
selecting mutants that may cross-react with other inhibitors. For 
instance, genotype 1b replicons subjected to a single protease 
inhibitor (ie, TPR or BPR) selected NS3 protease resistant 
variants such as substitutions A156T/A156V and R109 K to 
make the virus resistant to all other inhibitors. Some authors 
argue that in most cases, mutation A156T significantly reduces 
NS3/4A catalytic efficiency, polyprotein processing, and repli-
con fitness, but RNA viruses like HCV having an enormous 
capacity of adaptation and second-site mutations such as 
P89 L, Q86R, and G162R have been described to partially 
reverse A156T-associated defects in polyprotein processing 
and/or replicon fitness, without significantly reducing resis-
tance to the protease inhibitor.121–124 As resistance is a major 
problem, the FDA has restricted the use of monotherapy to 
3 days in early studies and then SOC has to be added.
Key issues relevant to the development of resistance 
include the number of mutations needed to introduce the 
required coding change(s), the replication capacity of the 
variant virus, the prevalence of the variant within the quasi-
species, the level of resistance that it confers to the virus, and 
the potency and bioavailability of the antiviral agent.125 Other 
viral factors include viral quasispecies heterogeneity and, 
to a less extent, specific mutations within the core, E2, and 
NS5 A coding regions. The availability of recently developed 
platforms for massive parallel high-throughput sequencing 
of both viral populations and host polymorphisms (ie, IL28 
and MHC haplotypes for HCV), especially those capable of 
clonally sequencing long fragments (ie, 454/Roche), should 
facilitate optimization of treatment.
Table 3 SOC-free DAA combinations
Agent 1 Agent 2 Phase of  
development
RG7227 (ITMN-191) 
(Danoprevir)  
(protease inhibitor)
RG7128  
(polymerase inhibitor)
Phase I
BMS-650032  
(protease inhibitor)
BMS-790052  
(NS5A inhibitor)
Phase I
GS9256  
(protease inhibitor)
Tegobuvir  
(polymerase inhibitor)
Phase II
Telaprevir  
(protease inhibitor)
vX-222  
(polymerase inhibitor)
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Conclusion
Persistent HCV infection is a leading cause of chronic hepa-
titis, cirrhosis, and HCC and the major indication for liver 
transplantation in adults. In contrast to HBV and HIV , HCV 
can be permanently eradicated from the infected host. Current 
SOC with pegylated IFN-α 2 and RBV for 48 weeks eradi-
cates infection in ∼50% of HCV genotype 1-infected patients 
and is associated with significant side effects, which limit its 
effectiveness in many cases (ie, dialysis and HIV-infected 
patients, transplant recipients, etc.), and are frequently asso-
ciated with poor compliance or treatment discontinuation, 
requiring specialized and frequent monitoring.
In recent years, host (IL-28B polymorphisms, MHC hap-
lotypes, and several polymorphisms in cytokine/chemokines 
and IFN signaling pathways) and viral factors (genotype, 
viral load, quasispecies complexity, and mutations in viral-
encoded proteins) have been strongly associated with SOC 
treatment outcome. Hence, accurately predicting response to 
SOC (and to any available DAA) will require   identification 
of host and viral factors independently associated with 
treatment outcome to design cost-effective, individualized 
treatment strategies.
To overcome the limited efficacy of SOC, more than 50 
DAAs, designed to target viral-encoded proteins essential 
in the HCV life cycle (ie, NS3 protease, NS5B polymerase, 
NS5A, etc.), are currently under development. Phase III trials 
have just been completed for two protease inhibitors (TPR 
and BPR) and have shown a highly significant increase in 
viral eradication rates when given in association with SOC 
treatment. The rapid selection of resistant mutants associ-
ated with the high mutation rate of HCV have clearly shown 
that DAAs cannot be given in monotherapy and SOC–DAA 
combinations will be required in the near future.
Nonetheless, the ultimate goal of HCV treatment (HCV 
eradication in every patient within the shortest time interval 
and minimum side effects) will imply the design of IFN-free 
specifically targeted anti-HCV treatment (STAT-C) strate-
gies with a combination of DAAs targeting different steps 
of the HCV life cycle.
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